Artal Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Artal Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-200,000	Closed	-$26M	–	151
2020 Q4	$26M	Buy	+200,000	New	+$26.7M	0.56%	48
2020 Q3	–	Sell	-100,000	Closed	-$14.8M	–	138
2020 Q2	$14.8M	Buy	+100,000	New	+$13.5M	0.41%	55
2019 Q3	–	Sell	-150,000	Closed	-$10.9M	–	104
2019 Q2	$10.9M	Buy	+150,000	New	+$11.5M	0.44%	48
2019 Q1	–	Sell	-300,000	Closed	-$21.9M	–	105
2018 Q4	$21.9M	Buy	300,000 +200,000	+200%	+$15.4M	0.81%	27
2018 Q3	$8.75M	Hold	100,000	–	–	0.23%	59
2018 Q2	$9.85M	Buy	+100,000	New	+$9.92M	0.21%	48
2018 Q1	–	Sell	-200,000	Closed	-$25.4M	–	111
2017 Q4	$25.4M	Buy	+200,000	New	+$25.1M	0.38%	24
2017 Q1	–	Sell	-200,000	Closed	-$7.49M	–	97
2016 Q4	$7.49M	Buy	200,000 +100,000	+100%	+$4.19M	0.17%	44
2016 Q3	$6.78M	Sell	100,000 -200,000	-67%	-$14.1M	0.13%	45
2016 Q2	$16.6M	Buy	300,000 +150,000	+100%	+$9.45M	0.34%	21
2016 Q1	$9.42M	Buy	+150,000	New	+$9.97M	0.18%	36
2015 Q4	–	Sell	-50,000	Closed	-$4.02M	–	82
2015 Q3	$4.02M	Buy	+50,000	New	+$5.56M	0.09%	60

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Artal Group's ALNY Position: Q4 2023 in Review

Artal Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 936 shares — an estimated $166K sold.

Artal Group first reported a position in ALNY in Q4 2013 and held it in 37 quarters. The position peaked at $133M in Q2 2020. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Artal Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Artal Group sold 936 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $166K.
Artal Group first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 37 quarters.
Artal Group's Alnylam Pharmaceuticals position peaked at $133M in Q2 2020.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.